Pharmacokinetics and Pharmacodynamics of Repository Corticotropin Injection Compared With Synthetic ACTH 1‐24 Depot and Methylprednisolone in Healthy Subjects

Repository corticotropin injection (RCI; Acthar Gel) is a naturally sourced complex mixture of adrenocorticotropic hormone (ACTH) analogs and other pituitary peptides. This phase 1, single‐center, open‐label, randomized parallel study directly compared the pharmacokinetics and pharmacodynamics of RC...

Full description

Saved in:

Bibliographic Details
Published in	Clinical pharmacology in drug development Vol. 11; no. 4; pp. 502 - 515
Main Authors	Poola, Nagaraju, Due, Bryan, Wright, Dale, Brooks, Leah R., Zaman, Fahima
Format	Journal Article
Language	English
Published	United States 01.04.2022
Subjects	Adrenocorticotropic Hormone - pharmacology Animals Cosyntropin - pharmacology Healthy Volunteers Humans Hydrocortisone Methylprednisolone - pharmacology Swine pharmacokinetics RCI synthetic ACTH1-24 depot pharmacodynamics repository corticotropin injection
Online Access	Get full text
ISSN	2160-763X 2160-7648
DOI	10.1002/cpdd.1020

Cover

Abstract	Repository corticotropin injection (RCI; Acthar Gel) is a naturally sourced complex mixture of adrenocorticotropic hormone (ACTH) analogs and other pituitary peptides. This phase 1, single‐center, open‐label, randomized parallel study directly compared the pharmacokinetics and pharmacodynamics of RCI and synthetic ACTH 1‐24 depot. Methylprednisolone was included to estimate the steroidogenic exposure of RCI and synthetic ACTH 1‐24 depot when used to treat nephrotic syndrome. A total of 48 healthy subjects aged 18 to 50 years were randomly assigned 1:1:1 to RCI (80 IU subcutaneously twice weekly on study days 1 and 4), synthetic ACTH 1‐24 depot (1 mg subcutaneously twice weekly on study days 1 and 4), or methylprednisolone (32 mg orally once daily on study days 1 through 6). After 2 doses, RCI induced about 5‐fold lower free cortisol exposure and an estimated 4‐fold lower steroidogenic exposure than synthetic ACTH 1‐24 depot. The lower endogenous cortisol response of RCI was achieved despite higher observed mean plasma concentrations of N25‐deamidated porcine ACTH 1‐39 (the pharmacokinetic marker for RCI) than of ACTH 1‐24 . The different pharmacodynamic properties demonstrated by RCI and synthetic ACTH 1‐24 depot in this study suggest that these products in the ACTH class are not interchangeable.
AbstractList	Repository corticotropin injection (RCI; Acthar Gel) is a naturally sourced complex mixture of adrenocorticotropic hormone (ACTH) analogs and other pituitary peptides. This phase 1, single‐center, open‐label, randomized parallel study directly compared the pharmacokinetics and pharmacodynamics of RCI and synthetic ACTH 1‐24 depot. Methylprednisolone was included to estimate the steroidogenic exposure of RCI and synthetic ACTH 1‐24 depot when used to treat nephrotic syndrome. A total of 48 healthy subjects aged 18 to 50 years were randomly assigned 1:1:1 to RCI (80 IU subcutaneously twice weekly on study days 1 and 4), synthetic ACTH 1‐24 depot (1 mg subcutaneously twice weekly on study days 1 and 4), or methylprednisolone (32 mg orally once daily on study days 1 through 6). After 2 doses, RCI induced about 5‐fold lower free cortisol exposure and an estimated 4‐fold lower steroidogenic exposure than synthetic ACTH 1‐24 depot. The lower endogenous cortisol response of RCI was achieved despite higher observed mean plasma concentrations of N25‐deamidated porcine ACTH 1‐39 (the pharmacokinetic marker for RCI) than of ACTH 1‐24 . The different pharmacodynamic properties demonstrated by RCI and synthetic ACTH 1‐24 depot in this study suggest that these products in the ACTH class are not interchangeable. Repository corticotropin injection (RCI; Acthar Gel) is a naturally sourced complex mixture of adrenocorticotropic hormone (ACTH) analogs and other pituitary peptides. This phase 1, single-center, open-label, randomized parallel study directly compared the pharmacokinetics and pharmacodynamics of RCI and synthetic ACTH depot. Methylprednisolone was included to estimate the steroidogenic exposure of RCI and synthetic ACTH depot when used to treat nephrotic syndrome. A total of 48 healthy subjects aged 18 to 50 years were randomly assigned 1:1:1 to RCI (80 IU subcutaneously twice weekly on study days 1 and 4), synthetic ACTH depot (1 mg subcutaneously twice weekly on study days 1 and 4), or methylprednisolone (32 mg orally once daily on study days 1 through 6). After 2 doses, RCI induced about 5-fold lower free cortisol exposure and an estimated 4-fold lower steroidogenic exposure than synthetic ACTH depot. The lower endogenous cortisol response of RCI was achieved despite higher observed mean plasma concentrations of N25-deamidated porcine ACTH (the pharmacokinetic marker for RCI) than of ACTH . The different pharmacodynamic properties demonstrated by RCI and synthetic ACTH depot in this study suggest that these products in the ACTH class are not interchangeable.
Author	Poola, Nagaraju Brooks, Leah R. Due, Bryan Wright, Dale Zaman, Fahima
Author_xml	– sequence: 1 givenname: Nagaraju surname: Poola fullname: Poola, Nagaraju organization: Mallinckrodt Pharmaceuticals Hampton New Jersey USA – sequence: 2 givenname: Bryan surname: Due fullname: Due, Bryan organization: Mallinckrodt Pharmaceuticals Hampton New Jersey USA – sequence: 3 givenname: Dale surname: Wright fullname: Wright, Dale organization: Mallinckrodt Pharmaceuticals Hampton New Jersey USA – sequence: 4 givenname: Leah R. surname: Brooks fullname: Brooks, Leah R. organization: Mallinckrodt Pharmaceuticals Hampton New Jersey USA – sequence: 5 givenname: Fahima surname: Zaman fullname: Zaman, Fahima organization: Mallinckrodt Pharmaceuticals Hampton New Jersey USA
BackLink	https://www.ncbi.nlm.nih.gov/pubmed/34528408$$D View this record in MEDLINE/PubMed
BookMark	eNplkT9OwzAYxS1UREvpwAWQV4ZS20kTd6zKn1YqAtFKsEWO7aguiR3Z7pCNI3AEzsZJcChlAC_-9PS-n_X8TkFHGy0BOMfoCiNERrwWIkwEHYEewQkapklMO79z9NIFA-e2KJwEYYzjE9CN4jGhMaI98PG4YbZi3LwqLb3iDjIt4EEUjWZVK5oCPsnaOOWNbeDM2GA13ppaabjQW8m9MjroVc2sFPBZ-Q1cNdpvWiacztZziD_f3kkMrwPGfz9yL_2mKevg18qZMqSCgTaXrAw6XO3yFuvOwHHBSicHP3cfrG9v1rP5cPlwt5hNl0M-SelQ8BA6kZKlCYkok5JMiiKnMU9jHo0RKyKCcUoFSghJcjnBpBA5ogLnlOQI51EfXOyx9S6vpMhqqypmm-zwU8Ew2hu4Nc5ZWWRcedbG9papMsMoa-vI2jqyto6wcfln4wD97_0CJ3KO7g
CitedBy_id	crossref_primary_10_1007_s12325_022_02160_y crossref_primary_10_1007_s40123_022_00501_2 crossref_primary_10_7878_jjsogd_44_1_2_20 crossref_primary_10_1007_s40744_023_00545_1 crossref_primary_10_1007_s40261_023_01303_5 crossref_primary_10_1111_cns_13789 crossref_primary_10_1007_s41030_022_00181_0 crossref_primary_10_1089_jir_2022_0257 crossref_primary_10_1016_j_rmed_2023_107422 crossref_primary_10_1080_00498254_2022_2119180 crossref_primary_10_1111_epi_17918 crossref_primary_10_1007_s10309_024_00685_6 crossref_primary_10_1007_s41030_023_00222_2
Cites_doi	10.1111/j.0954-6820.1960.tb06663.x 10.1100/tsw.2010.173 10.1002/j.1552-4604.1997.tb04266.x 10.1053/j.ajkd.2005.10.016 10.1186/s13075-015-0823-y 10.1053/j.ajkd.2013.02.044 10.4187/respcare.06314 10.1136/bmj.j1415 10.1177/1756285613518599 10.1136/lupus-2016-000180 10.1007/s40744-020-00236-1 10.1023/A:1016287104656 10.1097/TP.0000000000002320 10.1177/0961203314532562 10.3390/ijms18102201 10.1016/j.transproceed.2019.04.052 10.1080/10799893.2020.1859533 10.1002/cpdd.894 10.1007/s12325-018-0759-0 10.2147/DDDT.S17521 10.1186/s12882-016-0241-7 10.1016/j.coph.2016.10.006 10.1111/j.1749-6632.1977.tb41843.x 10.1136/lupus-2017-000240 10.1016/j.ekir.2019.10.007 10.1111/cei.13089 10.1016/S0140-6736(09)60326-3 10.1016/0014-5793(71)80520-3 10.1007/s40744-020-00199-3 10.1530/EC-18-0421 10.1007/s12026-014-8565-5
ContentType	Journal Article
Copyright	2021 Mallinckrodt Pharmaceuticals. Clinical Pharmacology in Drug Development published by Wiley Periodicals LLC on behalf of American College of Clinical Pharmacology.
Copyright_xml	– notice: 2021 Mallinckrodt Pharmaceuticals. Clinical Pharmacology in Drug Development published by Wiley Periodicals LLC on behalf of American College of Clinical Pharmacology.
DBID	AAYXX CITATION CGR CUY CVF ECM EIF NPM
DOI	10.1002/cpdd.1020
DatabaseName	CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed
DatabaseTitle	CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid)
DatabaseTitleList	CrossRef MEDLINE
Database_xml	– sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database
DeliveryMethod	fulltext_linktorsrc
Discipline	Pharmacy, Therapeutics, & Pharmacology
EISSN	2160-7648
EndPage	515
ExternalDocumentID	34528408 10_1002_cpdd_1020
Genre	Randomized Controlled Trial Research Support, Non-U.S. Gov't Journal Article
GroupedDBID	05W 0R~ 1OC 33P 3SF 52U 52V 53G 8-1 AAESR AAEVG AAHHS AAHQN AAIPD AAMNL AANHP AANLZ AAONW AAXRX AAYCA AAYXX AAZKR ABCUV ABDBF ABJNI ABQWH ABXGK ACAHQ ACBWZ ACCFJ ACCZN ACGFS ACGOF ACMXC ACPOU ACRPL ACUHS ACXBN ACXQS ACYXJ ADBBV ADBTR ADEOM ADIZJ ADKYN ADMGS ADNMO ADOZA ADXAS ADZMN ADZOD AEEZP AEIGN AEIMD AENEX AEQDE AEUYR AEYWJ AFBPY AFFPM AFGKR AFWVQ AGHNM AGQPQ AGYGG AHBTC AIACR AITYG AIURR AIWBW AJBDE ALMA_UNASSIGNED_HOLDINGS ALUQN ALVPJ AMBMR AMYDB ASPBG ATUGU AVWKF AZFZN AZVAB BDRZF BFHJK BHBCM BMXJE BNHUX BOGZA BRXPI C45 CITATION DCZOG DPXWK DRFUL DRMAN DRSTM EBS EJD FUBAC G-S GODZA H13 HGLYW KBYEO LATKE LEEKS LH4 LITHE LOXES LSO LUTES LW6 LYRES MEWTI MRFUL MRMAN MRSTM MSFUL MSMAN MSSTM MXFUL MXMAN MXSTM MY~ O66 O9- OVD P2W PQQKQ R.K ROL SUPJJ TEORI TUS WBKPD WIH WIJ WIK WOHZO WOIKV WPGGZ WXSBR ZZTAW -MK AFPWT CGR CUY CVF ECM EIF NPM WYJ
ID	FETCH-LOGICAL-c978-dc6486eea76238aee29ffb84c74c350af321178d06226be912fdb08d1b82b01b3
ISSN	2160-763X
IngestDate	Wed Feb 19 02:26:16 EST 2025 Thu Apr 24 23:09:12 EDT 2025 Tue Jul 01 00:19:14 EDT 2025
IsPeerReviewed	true
IsScholarly	true
Issue	4
Keywords	pharmacokinetics RCI synthetic ACTH1-24 depot pharmacodynamics repository corticotropin injection
Language	English
License	2021 Mallinckrodt Pharmaceuticals. Clinical Pharmacology in Drug Development published by Wiley Periodicals LLC on behalf of American College of Clinical Pharmacology.
LinkModel	OpenURL
MergedId	FETCHMERGED-LOGICAL-c978-dc6486eea76238aee29ffb84c74c350af321178d06226be912fdb08d1b82b01b3
PMID	34528408
PageCount	14
ParticipantIDs	pubmed_primary_34528408 crossref_citationtrail_10_1002_cpdd_1020 crossref_primary_10_1002_cpdd_1020
ProviderPackageCode	CITATION AAYXX
PublicationCentury	2000
PublicationDate	2022-04-00
PublicationDateYYYYMMDD	2022-04-01
PublicationDate_xml	– month: 04 year: 2022 text: 2022-04-00
PublicationDecade	2020
PublicationPlace	United States
PublicationPlace_xml	– name: United States
PublicationTitle	Clinical pharmacology in drug development
PublicationTitleAlternate	Clin Pharmacol Drug Dev
PublicationYear	2022
References	e_1_2_10_24_1 e_1_2_10_22_1 e_1_2_10_20_1 e_1_2_10_2_1 e_1_2_10_4_1 e_1_2_10_18_1 e_1_2_10_3_1 e_1_2_10_19_1 e_1_2_10_6_1 e_1_2_10_16_1 e_1_2_10_17_1 e_1_2_10_8_1 e_1_2_10_14_1 e_1_2_10_37_1 e_1_2_10_7_1 e_1_2_10_15_1 e_1_2_10_36_1 e_1_2_10_12_1 e_1_2_10_9_1 e_1_2_10_13_1 e_1_2_10_34_1 e_1_2_10_10_1 e_1_2_10_33_1 e_1_2_10_11_1 Healy LM (e_1_2_10_21_1) 2017; 23 e_1_2_10_32_1 Brombacher PJ (e_1_2_10_35_1) 1969; 7 e_1_2_10_31_1 Nicolaides NC (e_1_2_10_30_1) 2000 Wright D (e_1_2_10_23_1) 2019; 78 Zoorob RJ (e_1_2_10_5_1) 1998; 58 e_1_2_10_29_1 e_1_2_10_27_1 e_1_2_10_28_1 e_1_2_10_25_1 e_1_2_10_26_1
References_xml	– ident: e_1_2_10_34_1 doi: 10.1111/j.0954-6820.1960.tb06663.x – ident: e_1_2_10_36_1 doi: 10.1100/tsw.2010.173 – ident: e_1_2_10_33_1 doi: 10.1002/j.1552-4604.1997.tb04266.x – ident: e_1_2_10_29_1 doi: 10.1053/j.ajkd.2005.10.016 – ident: e_1_2_10_20_1 doi: 10.1186/s13075-015-0823-y – ident: e_1_2_10_27_1 doi: 10.1053/j.ajkd.2013.02.044 – ident: e_1_2_10_4_1 doi: 10.4187/respcare.06314 – ident: e_1_2_10_6_1 doi: 10.1136/bmj.j1415 – ident: e_1_2_10_10_1 doi: 10.1177/1756285613518599 – volume: 23 start-page: 777 issue: 3 year: 2017 ident: e_1_2_10_21_1 article-title: Melanocortin receptor mediated anti‐inflammatory effect of repository corticotropin injection on human monocyte‐derived macrophages [ECTRIMS‐ACTRIMS abstract EP1481] publication-title: Mult Scler J – ident: e_1_2_10_12_1 doi: 10.1136/lupus-2016-000180 – volume-title: Glucocorticoid Therapy and Adrenal Suppression year: 2000 ident: e_1_2_10_30_1 – ident: e_1_2_10_19_1 doi: 10.1007/s40744-020-00236-1 – ident: e_1_2_10_32_1 doi: 10.1023/A:1016287104656 – ident: e_1_2_10_15_1 doi: 10.1097/TP.0000000000002320 – ident: e_1_2_10_11_1 doi: 10.1177/0961203314532562 – ident: e_1_2_10_31_1 doi: 10.3390/ijms18102201 – ident: e_1_2_10_16_1 doi: 10.1016/j.transproceed.2019.04.052 – ident: e_1_2_10_24_1 doi: 10.1080/10799893.2020.1859533 – ident: e_1_2_10_28_1 doi: 10.1002/cpdd.894 – ident: e_1_2_10_2_1 doi: 10.1007/s12325-018-0759-0 – ident: e_1_2_10_9_1 doi: 10.2147/DDDT.S17521 – ident: e_1_2_10_13_1 doi: 10.1186/s12882-016-0241-7 – ident: e_1_2_10_37_1 doi: 10.1016/j.coph.2016.10.006 – ident: e_1_2_10_26_1 doi: 10.1111/j.1749-6632.1977.tb41843.x – volume: 58 start-page: 443 issue: 2 year: 1998 ident: e_1_2_10_5_1 article-title: A different look at corticosteroids publication-title: Am Fam Physician – ident: e_1_2_10_14_1 doi: 10.1136/lupus-2017-000240 – ident: e_1_2_10_18_1 doi: 10.1016/j.ekir.2019.10.007 – ident: e_1_2_10_22_1 doi: 10.1111/cei.13089 – ident: e_1_2_10_7_1 doi: 10.1016/S0140-6736(09)60326-3 – ident: e_1_2_10_25_1 doi: 10.1016/0014-5793(71)80520-3 – volume: 78 start-page: 1504 issue: 2 year: 2019 ident: e_1_2_10_23_1 article-title: Reduced steriodogenic activity of repository corticotropin injection (RCI) induces a distinct cytokine response following T cell activation [EULAR abstract AB0082] publication-title: Ann Rheum Dis – ident: e_1_2_10_17_1 doi: 10.1007/s40744-020-00199-3 – ident: e_1_2_10_8_1 doi: 10.1530/EC-18-0421 – volume: 7 start-page: 291 issue: 3 year: 1969 ident: e_1_2_10_35_1 article-title: Comparative trial with highly purified natural ACTH, synthetic ACTH 1‐24 peptide and synthetic ACTH 1‐39 peptide publication-title: Z Klin Chem Klin Biochem – ident: e_1_2_10_3_1 doi: 10.1007/s12026-014-8565-5
SSID	ssj0000601114
Score	2.2062306
Snippet	Repository corticotropin injection (RCI; Acthar Gel) is a naturally sourced complex mixture of adrenocorticotropic hormone (ACTH) analogs and other pituitary...
SourceID	pubmed crossref
SourceType	Index Database Enrichment Source
StartPage	502
SubjectTerms	Adrenocorticotropic Hormone - pharmacology Animals Cosyntropin - pharmacology Healthy Volunteers Humans Hydrocortisone Methylprednisolone - pharmacology Swine
Title	Pharmacokinetics and Pharmacodynamics of Repository Corticotropin Injection Compared With Synthetic ACTH 1‐24 Depot and Methylprednisolone in Healthy Subjects
URI	https://www.ncbi.nlm.nih.gov/pubmed/34528408
Volume	11
hasFullText	1
inHoldings	1
isFullTextHit
isPrint
link	http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1bb9MwFLZKJ6G9TNwZN1kITUgsLHGcxHnsMqYKMVSJIPZWObYzGF0Tde1D-TH8AH4lx3acpNuQgJeoSlxb7ffpXJxzPiP0KkgFL5NYeURS4VFCAo_FQnikJDGTScFSo85_8jEef6bvT6PTweBXr2pptSzeih839pX8D6pwD3DVXbL_gGw7KdyAz4AvXAFhuP4VxpNGd_o7hIqt3LK7Ke1Z843ciCnO0u_Ts0rPUy0XulMKzMO5soeFZ64Y_Yvemf20nkNkqMVcR1k-fhN4hIJpqitbj36iAN5ZDaPn3-AXVlZ5xHY0GVukJ73sx72Za8CsO6ls03EoF6sz17nVL8KZVJBzW_N_xhf8fNVF3Mpyct3xuttiOOKzXpkAJBCGph8U_9pURjYbHJAbd3UxyhhCEsS-l8RWkbO12kGPnbRngiPTwX3dNVipWVFLqeUq_P4YQLW-MBwJaQT-2medd2xrFt2jW2iLJBCnDdHW6PDo8Ljd0dPKNpBdOvkqnxy0i22j2-7rG_HPRiZjIpr8DtppUhE8sry6iwZqfg_tNfRZ7-O8a8273Md7eNKD7j76eZV8GJiBr5IPVyXuyIc3yIdb8mFHPqzJh1vyYU0-rMmHDfnMEtfJh2GuhnzYke8Byo_f5dnYaw778ITeyJAC8I2V4uCcQ8aVImlZFoyKhIow8nkZkiBImPRjyBcKlQaklIXPZFAwUvhBET5Ewzms-BhhwXmZhtrLM_jTU8KLREmZUkojcOai3EWvHQJT0Qjh6_NYZlMr4U2mGrepxm0XvWyH1lb95aZBjyyM7RCH9ZM_PnmKtjuqP0PD5WKlnkN0uyxeNLT6DTyyrxA
linkProvider	EBSCOhost
openUrl	ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Pharmacokinetics+and+Pharmacodynamics+of+Repository+Corticotropin+Injection+Compared+With+Synthetic+ACTH+1-24+Depot+and+Methylprednisolone+in+Healthy+Subjects&rft.jtitle=Clinical+pharmacology+in+drug+development&rft.au=Poola%2C+Nagaraju&rft.au=Due%2C+Bryan&rft.au=Wright%2C+Dale&rft.au=Brooks%2C+Leah+R&rft.date=2022-04-01&rft.eissn=2160-7648&rft.volume=11&rft.issue=4&rft.spage=502&rft_id=info:doi/10.1002%2Fcpdd.1020&rft_id=info%3Apmid%2F34528408&rft.externalDocID=34528408
thumbnail_l	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2160-763X&client=summon
thumbnail_m	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2160-763X&client=summon
thumbnail_s	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2160-763X&client=summon